4//SEC Filing
Mayne Pharma Ventures Pty Ltd 4
Accession 0001144204-18-065264
CIK 0001042418other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 6:09 AM ET
Size
9.6 KB
Accession
0001144204-18-065264
Insider Transaction Report
Form 4
Mayne Pharma Ventures Pty Ltd
Director10% Owner
Transactions
- Other
Common Stock
2018-07-15+184,798→ 198,290,930 total
Mayne Pharma International Pty Ltd
10% Owner
Transactions
- Other
Common Stock
2018-07-15+184,798→ 198,290,930 total
Mayne Pharma Group Ltd
10% Owner
Transactions
- Other
Common Stock
2018-07-15+184,798→ 198,290,930 total
Footnotes (2)
- [F1]On July 15, 2018, Mayne Pharma Ventures Pty Ltd ("Mayne Ventures") received a dividend of 184,798 shares of Common Stock paid by the Issuer on shares of Series B Convertible Preferred Stock held by Mayne Ventures, pursuant to the terms of such Series B Convertible Preferred Stock.
- [F2]These securities are directly owned by Mayne Ventures. This report is filed jointly by Mayne Ventures, Mayne Pharma International Pty Ltd ("Mayne International") and Mayne Pharma Group Limited ("Mayne Group"). Mayne Group holds 100% of the issued and outstanding equity securities of Mayne International, and Mayne International holds 100% of the issued and outstanding equity securities of Mayne Ventures. Consequently, Mayne Group and Mayne International may be deemed to beneficially own the securities that are the subject to this report indirectly, but disclaim beneficial ownership of such securities except to the extent of their pecuniary interests therein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Mayne Ventures is deemed a director by deputization by virtue of its representation on the Board of Directors of the Issuer.
Documents
Issuer
HedgePath Pharmaceuticals, Inc.
CIK 0001042418
Entity typeother
IncorporatedAustralia
Related Parties
1- filerCIK 0001611535
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 6:09 AM ET
- Size
- 9.6 KB